

## TOFATHRE

**For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory**

abbreviated prescribing information for TOFATHRE (Tofacitinib Tablets 5 mg)

[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com) ]

**PHARMACOLOGICAL PROPERTIES:** Tofacitinib is a potent, selective inhibitor of the JAK family. In enzymatic assays, tofacitinib inhibits JAK1, JAK2, JAK3, and to a lesser extent TyK2. In contrast, tofacitinib has a high degree of selectivity against other kinases in the human genome. In human cells, tofacitinib preferentially inhibits signalling by heterodimeric cytokine receptors that associate with JAK3 and/or JAK1 with functional selectivity over cytokine receptors that signal via pairs of JAK2. Inhibition of JAK1 and JAK3 by tofacitinib attenuates signalling of interleukins (IL-2, -4, -6, -7, -9, -15, -21) and type I and type II interferons, which will result in modulation of the immune and inflammatory response.

**INDICATION:** For the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to Methotrexate. It may be used as monotherapy or in combination with methotrexate or other nonbiologic disease.

**DOSAGE AND ADMINISTRATION:** TOFATHRE Film coated 5 mg tablet should be taken as directed by Physician.

**CONTRAINDICATION:** Hypersensitivity to the active substance or to any of the excipients. Active tuberculosis (TB), serious infections such as sepsis, or opportunistic infections. Severe hepatic impairment. Pregnancy and lactation.

**WARNINGS & PRECAUTIONS:** The signs and symptoms of orthostasis (postural hypotension, dizziness, and vertigo) were detected more frequently in tofathre treated patients. *Use in patients over 65 years of age:* increased risk of serious infections, myocardial infarction, and malignancies with tofacitinib. *Combination with other therapies:* Tofacitinib should be avoided in combination with biologics such as TNF antagonists, interleukin (IL)-1R antagonists, IL-6R antagonists, anti-CD20 monoclonal antibodies, IL-17 antagonists, IL-12/IL-23 antagonists, anti-integrins, selective co-stimulation modulators and potent immunosuppressants such as azathioprine, 6-mercaptopurine, ciclosporine and tacrolimus because of the possibility of increased immunosuppression and increased risk of infection. Venous thromboembolism (VTE), Tuberculosis, Viral reactivation, Serious and some fatal infections, Major adverse cardiovascular events (MACE), Malignancy and lymphoproliferative disorder, Non-melanoma skin cancer, Interstitial lung disease, Gastrointestinal perforations, Liver enzymes, Hypersensitivity have been observed in patients taking tofacitinib

**DRUG INTERACTIONS:** *Potential for other medicinal products to influence the pharmacokinetics (PK) of tofacitinib:* Since tofacitinib is metabolised by CYP3A4, interaction with medicinal products that inhibit or induce CYP3A4 is likely. Tofacitinib exposure is increased when coadministered with potent inhibitors of CYP3A4 (e.g., ketoconazole) or when administration of one or more concomitant medicinal products results in both moderate inhibition of CYP3A4 and potent inhibition of CYP2C19 (e.g., fluconazole). *Potential for tofacitinib to influence the PK of other medicinal products:* Coadministration of tofacitinib did not have an effect on the PK of oral contraceptives, levonorgestrel and ethinyl estradiol, in healthy female volunteers. *Paediatric population:* Interaction studies have only been performed in adults.

**ADVERSE REACTIONS:** Fever and chills, Cough, Skin blisters, Stomach ache, Persistent headaches, Stomach or abdominal pain, Blood in the stool, Unexplained changes in bowel habits, Chest tightness, wheezing, Severe dizziness or light-headedness, Swelling of the lips, tongue or throat, Hives (itching or skin rash), Chest pain or pain in upper back, Swelling of the leg or arm, Leg pain or tenderness, Redness or discoloration in the leg or arm, Severe chest pain or tightness (that may spread to arms, jaw, neck, back), Shortness of breath, Cold sweat.

**MARKETED BY:**



TORRENT PHARMACEUTICALS LTD.

**IN/ TOFATHRE 5 mg/JUN-22/01/ABPI**

(Additional information is available on request)